Trial · NCT01145625
Clinical Trial in Females With Female Pattern Hair Loss
NCT01145625, Phase 3, Completed, Johnson & Johnson Healthcare Products Division of McNEIL-PPC, Inc.; results first posted 2014-04-25
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Clinical Trial in Females With Female Pattern Hair Loss. Trials, record NCT01145625. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT01145625
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Clinical Trial in Females With Female Pattern Hair Loss
- NCT number
- NCT01145625
- Status
- Completed
- Phases
- Phase 3
- Enrollment
- 322 participants, actual
- Lead sponsor
- Johnson & Johnson Healthcare Products Division of McNEIL-PPC, Inc.
- Conditions
- Alopecia
- Interventions
- 5% Minoxidil, 2% Minoxidil
- First posted
- 2010-06-16
- Last updated
- 2014-05-22
- Other registries' IDs
- eudract:2009-018109-29
- Results first posted
- 2014-04-25
Source ClinicalTrials.gov
Registered outcomes3
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Target Area Hair Count (TAHC) | Baseline to Week 24 | Number of hairs in the area being examined as measured by macrophotography. |
| Secondary | Target Area Hair Count (TAHC) | Baseline to Week 12 | Number of hairs in the area being examined as measured by macrophotography |
| Other | Target Area Hair Count (TAHC) | Baseline to Week 52 | Number of hairs in the area being examined as measured by macrophotography. |
Source ClinicalTrials.gov
Outcomes3
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Target Area Hair Count (TAHC) | Baseline to Week 24 | Intent to Treat (ITT) population defined as all participants randomly assigned to a treatment group who received dispensed investigational product. | hairs per centimeter squared | MEAN |
| SECONDARY | Target Area Hair Count (TAHC) | Baseline to Week 12 | Intent-to-Treat (ITT) population defined as all participants randomly assigned to a treatment group who received dispensed investigational product. | hairs per centimeter squared | MEAN |
| OTHER_PRE_SPECIFIED | Target Area Hair Count (TAHC) | Baseline to Week 52 | Intent to Treat (ITT) population defined as all participants randomly assigned to a treatment group who received dispensed investigational product. | hairs per centimeter squared | MEAN |
Source ClinicalTrials.gov
Results by group18
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Target Area Hair Count (TAHC) | 2% MTS | Baseline | 167.3 | Standard Deviation 55.0 | hairs per centimeter squared |
| Target Area Hair Count (TAHC) | 5% MTF | Baseline | 169.7 | Standard Deviation 58.6 | hairs per centimeter squared |
| Target Area Hair Count (TAHC) | 2% MTS | Week 24 | 192.8 | Standard Deviation 57.0 | hairs per centimeter squared |
| Target Area Hair Count (TAHC) | 5% MTF | Week 24 | 194.4 | Standard Deviation 64.7 | hairs per centimeter squared |
| Target Area Hair Count (TAHC) | 2% MTS | Change from Baseline to Week 24 | 23.8 | Standard Deviation 24.7 | hairs per centimeter squared |
| Target Area Hair Count (TAHC) | 5% MTF | Change from Baseline to Week 24 | 23.7 | Standard Deviation 22.9 | hairs per centimeter squared |
| Target Area Hair Count (TAHC) | 2% MTS | Baseline | 167.3 | Standard Deviation 55.0 | hairs per centimeter squared |
| Target Area Hair Count (TAHC) | 5% MTF | Baseline | 169.7 | Standard Deviation 58.6 | hairs per centimeter squared |
| Target Area Hair Count (TAHC) | 2% MTS | Week 12 | 190.7 | Standard Deviation 56.9 | hairs per centimeter squared |
| Target Area Hair Count (TAHC) | 5% MTF | Week 12 | 191.8 | Standard Deviation 62.6 | hairs per centimeter squared |
1 to 10 of 18Source ClinicalTrials.gov
See all 18 results by groupParticipant flow6
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | 2% MTS | 161 | |
| Overall Study | STARTED | 5% MTF | 161 | |
| Overall Study | COMPLETED | 2% MTS | 137 | |
| Overall Study | COMPLETED | 5% MTF | 130 | |
| Overall Study | NOT COMPLETED | 2% MTS | 24 | |
| Overall Study | NOT COMPLETED | 5% MTF | 31 |
Source ClinicalTrials.gov
Adverse events64
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Nasopharyngitis | Infections and infestations | 2% MTS | 22 | 161 | |
| other | Nasopharyngitis | Infections and infestations | 5% MTF | 23 | 161 | |
| other | Upper respiratory tract infection | Infections and infestations | 2% MTS | 8 | 161 | |
| other | Upper respiratory tract infection | Infections and infestations | 5% MTF | 16 | 161 | |
| other | Sinusitis | Infections and infestations | 2% MTS | 12 | 161 | |
| other | Sinusitis | Infections and infestations | 5% MTF | 10 | 161 | |
| other | Urinary tract infection | Infections and infestations | 2% MTS | 3 | 161 | |
| other | Urinary tract infection | Infections and infestations | 5% MTF | 8 | 161 | |
| other | Bronchitis | Infections and infestations | 2% MTS | 2 | 161 | |
| other | Bronchitis | Infections and infestations | 5% MTF | 8 | 161 |
1 to 10 of 64Source ClinicalTrials.gov
See all 64 adverse eventsAdverse event totals6
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | 2% MTS | ||
| Total, all-cause mortality | 5% MTF | ||
| Total, other adverse events | 2% MTS | 118 | 161 |
| Total, other adverse events | 5% MTF | 109 | 161 |
| Total, serious adverse events | 2% MTS | 8 | 161 |
| Total, serious adverse events | 5% MTF | 2 | 161 |
Source ClinicalTrials.gov
Papers1
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as |
|---|---|
| 27391640 | DERIVED |
Source PubMed
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons1
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison |
|---|
| 2% MTS vs 5% MTF: serious adverse events |
Source Trial comparisons
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT01145625
GET https://conductscience.org/api/trials/v1/NCT01145625/events?page=2